Lorundrostat efficacy and safety
6 evidence topics · 26 sources
Summary: regulatory status and pivotal phase 3 trial Launch-HTN
Lorundrostat (MLS-101, formerly MT-4129) is an investigational oral aldosterone synthase inhibitor developed by Mineralys Therapeutics under an exclusive, worldwide license from Tanabe. Mineralys submitted a New Drug Application to the FDA in December 2025 for “the treatment of hypertension in combination with other antihypertensive drugs”, and the FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026; the company described the application as under review in November 2026. According to the company, the application includes the pivotal Launch-HTN (phase 3) and Advance-HTN (phase 2) trials, the Explore-CKD proof-of-concept trial, and the Transform-HTN open-label extension trial.
Launch-HTN (NCT06153693) was a phase 3, randomized, double-blind, placebo-controlled trial in adults with uncontrolled hypertension, including treatment-resistant hypertension, taking 2 to 5 antihypertensive medications, conducted at 159 sites in 13 countries (the registry lists 184 locations). Of 1,083 participants randomized in a 1:2:1 ratio, 1,078 received at least 1 dose: lorundrostat 50 mg for 6 weeks with possible escalation to 100 mg for 6 weeks (n = 270), lorundrostat 50 mg for 12 weeks (n = 538), or placebo (n = 270). For the primary endpoint, change in office systolic blood pressure at week 6 in the pooled 50 mg groups (n = 808) compared with placebo (n = 270), the least-squares mean change was −16.9 mm Hg (95% CI, −19.0 to −14.9) with lorundrostat and −7.9 mm Hg (95% CI, −11.5 to −4.2) with placebo, a difference of −9.1 mm Hg (95% CI, −13.3 to −4.9; P < .001); the March 2025 topline announcement states that the trial met its primary endpoint and gives the P value as < 0.0001. An office systolic blood pressure below 130 mm Hg at week 6 was achieved by 44.1% of participants receiving lorundrostat and 24.1% receiving placebo (odds ratio, 3.4; 95% CI, 1.5 to 7.8; P = .003), and the placebo-adjusted change at week 6 was −8.8 mm Hg (97.5% CI, −14.8 to −2.9) in participants taking 2 antihypertensive medications and −9.0 mm Hg (97.5% CI, −14.0 to −4.1) in those taking 3 or more (P < .001 for both).
At week 12, the placebo-adjusted change in the 50 mg group, a prespecified exploratory outcome, was −11.6 mm Hg (95% CI, −16.3 to −7.0; P < .001) in the publication; the topline announcement gives 11.7 mm Hg. In the escalation group, 92 of 270 participants (34.1%) were escalated to 100 mg, the placebo-adjusted change at week 12 was −8.4 mm Hg (95% CI, −13.6 to −3.2; P = .002), and the investigators state that the higher dose “provided no additional benefit to participants who did not reach the goal BP using the 50-mg/d dose”. In a secondary responder analysis of 790 participants with baseline office systolic blood pressure of 130 mm Hg or higher, 46.3% of the lorundrostat 50 mg group and 19.9% of the placebo group were below 130 mm Hg at week 12 (odds ratio, 3.86; 95% CI, 2.66-5.60). Treatment-emergent adverse events occurred in 538 of 1,078 participants (49.9%) and were mostly mild or moderate; serious adverse events occurred in 22 participants, 1 of them considered related to treatment, and 1 participant in the placebo group died (unrelated to treatment).
Summary: pivotal phase 2 trial Advance-HTN
Advance-HTN (NCT05769608) was a multicenter, randomized, double-blind, placebo-controlled phase 2 trial, described in the trial presentation as a “Phase 2b trial”, at 103 sites in the United States (the registry lists 104 locations). Participants taking 2 to 5 antihypertensive medications with an office blood pressure of 140/90 mm Hg or higher were switched for 3 weeks to a standardized regimen of indapamide 2.5 mg or hydrochlorothiazide 25 mg with olmesartan 40 mg, with amlodipine 10 mg added for those previously taking 3 to 5 medications, and those with a 24-hour ambulatory blood pressure of 130/80 mm Hg or higher were randomized. Of 926 participants who started the standardized regimen, 285 were randomized for 12 weeks: 94 to lorundrostat 50 mg daily (stable dose), 96 to lorundrostat 50 mg with an increase to 100 mg if systolic blood pressure was 130 mm Hg or higher after 4 weeks (dose adjustment), and 95 to placebo. The mean age was 60 years, and 150 participants (53%) were Black.
For the primary endpoint, change in 24-hour average systolic blood pressure from baseline to week 12, the least-squares mean change was −15.4 mm Hg with the stable dose, −13.9 mm Hg with dose adjustment, and −7.4 mm Hg with placebo; the placebo-adjusted changes were −7.9 mm Hg (97.5% CI, −13.3 to −2.6) and −6.5 mm Hg (97.5% CI, −11.8 to −1.2), with P values of 0.001 and 0.006 in the presentation. At week 4, the placebo-adjusted change in the combined lorundrostat groups (n = 188) was −5.3 mm Hg (95% CI, −8.4 to −2.3; P < 0.001), and 41% of participants receiving lorundrostat and 18% receiving placebo had a 24-hour average systolic blood pressure below 125 mm Hg (odds ratio, 3.3 [1.4 to 7.8]; P < 0.001). By standardized regimen, the week 4 placebo-adjusted change was −6.1 mm Hg (−10.8 to −1.4; P = 0.001) with 2 medications and −4.6 mm Hg (−10.6 to 1.5; P = 0.060) with 3. In the 19 participants escalated to 100 mg, office systolic blood pressure changed by −17.5 mm Hg (−30.3 to −4.7; P < 0.001) from baseline to week 12, and the presenters concluded that escalation from 50 to 100 mg “did not lower blood pressure more than 50 mg and was associated with numerically more adverse events”.
Serious adverse events occurred in 6 participants (6.4%) receiving the stable dose, 8 (8.4%) receiving dose adjustment, and 2 (2.1%) receiving placebo according to the annual report (6%, 8%, and 2% in the presentation), and were considered treatment related in 2%, 1%, and 0%. Hypotension was reported in 9%, 8%, and 3%, and hyponatremia in 9%, 11%, and 6% of the stable-dose, dose-adjustment, and placebo groups. A potassium level above 6.0 mmol/L occurred in 5 participants (5%) with the stable dose, 7 (7%) with dose adjustment, and none with placebo in the publication abstract; the annual report gives 5.3% and 7.4% at scheduled visits and 2.1% and 3.2% after exclusion of spurious results.
Summary: long-term open-label extension Transform-HTN
Transform-HTN (NCT05968430) is a phase 3, single-group, open-label extension for participants who completed Launch-HTN, Advance-HTN, or Explore-CKD, with 1,076 participants enrolled; the registry describes a 52-week open-label treatment period, a double-blind randomized treatment withdrawal substudy, and a status of “Active, not recruiting”. The results reported in November 2026 cover the Launch-HTN cohort: of 808 participants who received lorundrostat in Launch-HTN, 632 (78%) enrolled and received an additional 36 weeks of open-label lorundrostat, starting at 50 mg once daily (25 mg after a dose reduction in the parent trial) while continuing their existing antihypertensive medications. Of the 632, 549 (87%) completed treatment and 583 (92%) completed follow-up at week 48. The efficacy analysis (n = 504) excluded participants randomized to placebo in the 4-week withdrawal substudy.
The primary endpoint in the presentation, change in office systolic blood pressure from the Launch-HTN baseline to week 48 (the registry measure is stated at extension week 36), was −17.8 mmHg (95% CI, −19.6 to −16.0; P < 0.0001), a within-group change with no concurrent control group. At week 48, 56.0% of participants had an office systolic blood pressure below 130 mmHg (55.2% of those taking 2 antihypertensive drugs and 56.5% of those taking 3 or more), and serum aldosterone had decreased by 54.8% and plasma renin activity increased by 123.9% from baseline (not prespecified). No result was located for the randomized treatment withdrawal substudy, a registered primary outcome, or for participants who entered from Advance-HTN or Explore-CKD; the registry record states “No Results Posted”.
In the safety population (n = 632) during the 36-week open-label period, 413 participants (65.3%) had a treatment-emergent adverse event and 27 (4.3%) a serious adverse event, 2 (0.3%) of which investigators considered treatment related; no deaths occurred. Thirty-seven participants (5.9%) discontinued lorundrostat because of an adverse event, 10 (1.6%) of them for hyperkalemia. Hyperkalemia requiring trial drug modification occurred in 32 participants (5.1%), hyponatremia requiring trial drug modification in 28 (4.4%), symptomatic hypotension in 13 (2.1%), and serum potassium above 6.0 mmol/L confirmed by repeat testing in 16 (2.5%). The company states that serum potassium increased and eGFR decreased early in treatment and that “both remained stable through the open-label period to Week 48”.
Summary: phase 2 trials Target-HTN, Explore-CKD, and Explore-OSA
Target-HTN (NCT05001945) was a phase 2, randomized, double-blind, placebo-controlled, dose-ranging trial at 43 sites in the United States (the registry lists 44 locations) in adults with a systolic automated office blood pressure of 130 mm Hg or greater while taking 2 or more antihypertensive medications. Of 200 participants randomized, 163 with suppressed plasma renin (cohort 1) were assigned in a 1:1:1:1:1:1 ratio to placebo or lorundrostat 12.5, 50, or 100 mg once daily or 12.5 or 25 mg twice daily, and 37 with plasma renin activity above 1.0 ng/mL/h (cohort 2) were assigned in a 1:6 ratio to placebo or 100 mg once daily, for 8 weeks; randomization to the two 12.5 mg regimens stopped after an interim analysis. For the primary endpoint, change in systolic automated office blood pressure at week 8, the placebo group changed by −4.1 mm Hg, and the placebo-subtracted changes with once-daily doses were −1.5 mm Hg (90% CI, −8.3 to 5.3; P = .71) for 12.5 mg, −9.6 mm Hg (90% CI, −15.8 to −3.4; P = .01) for 50 mg, and −7.8 mm Hg (90% CI, −14.1 to −1.5; P = .04) for 100 mg, with no adjustment for multiplicity; the 2022 topline announcement gives these reductions as 1.4 mmHg, 9.7 mmHg (p=0.010), and 7.9 mmHg (p=0.037). Of the 200 participants, 110 (55%) had an adverse event; 3 serious adverse events occurred, 1 deemed treatment related (worsening hyponatremia with 100 mg in cohort 2 that required stopping the drug), and no adrenocortical insufficiency occurred.
Explore-CKD (NCT06150924) was a phase 2, randomized, double-blind, placebo-controlled, 2-period, 2-sequence crossover trial at 42 sites in the United States in participants with uncontrolled hypertension and chronic kidney disease (eGFR of 30 mL/min/1.73 m2 or higher) with albuminuria who were receiving an ACE inhibitor or ARB and an SGLT2 inhibitor. The publication reports 59 participants randomized (registry enrollment, 60) to lorundrostat 25 mg once daily and placebo in 4-week treatment periods separated by a 4-week washout. For the primary endpoint, the least-squares mean change in automated office systolic blood pressure was −9.3 mm Hg with lorundrostat and −1.8 mm Hg with placebo (placebo-adjusted change −7.5 mm Hg; 95% CI, −12.3 to −2.7; P = 0.0024), and in an exploratory analysis the placebo-adjusted change in spot UACR was −25.6% (P = 0.0015). At least 1 treatment-emergent adverse event was reported by 29 of 58 participants during lorundrostat treatment (50%) and 19 of 57 during placebo treatment (33%), serious adverse events by 2 (3.4%) and 0, and 2 participants discontinued treatment because of adverse events attributed to lorundrostat (hyperkalemia with acute kidney injury, and worsening CKD).
Explore-OSA (NCT06785454) was a phase 2, randomized, double-blind, placebo-controlled crossover trial in participants with a body mass index of 27 kg/m2 or higher, an apnea-hypopnea index of 15 events/hour or higher, and hypertension, who received lorundrostat 50 mg once daily in the evening and placebo for 4 weeks each, separated by a 2-week washout; the congress abstract describes 47 participants, and the registry and the company's NDA acceptance release describe 48. For the primary endpoint, change in apnea-hypopnea index, there was “no difference in AHI response between lorundrostat- and placebo-treated participants”. For the key secondary endpoint, office systolic blood pressure, the abstract reports a placebo-adjusted reduction of 10.1 mmHg (P=0.0089) in the preplanned parallel-arm analysis of the first treatment period and 6.2 mmHg (P<0.0003) in the crossover analysis of both periods; the company release reports the first-period result as within-group reductions of 11.1 mmHg (p < 0.0001) with lorundrostat and 1.0 mmHg (p = NS) with placebo. No serious adverse events were reported, and the company release states that no serum potassium value exceeded 5.5 mmol/L.
Summary: phase 1 and clinical pharmacology
The first-in-human study MT-4129-E01 (NCT02953132) was a four-part, randomized, double-blind, placebo-controlled study at a single center in the Netherlands from November 2016 to May 2017. Of 245 participants screened, 116 healthy white participants were randomized: 64 men received a single dose of 5 to 800 mg or placebo in the fasted state, 36 men received 40, 120, or 360 mg or placebo once daily for 7 days in the fed state, and in one cohort of 8 women (part 3) and one cohort of 8 men aged 65 years or older (part 4), 6 participants each received a single 100 mg dose and 2 received placebo. After single doses, the median Tmax was 1.0 to 1.5 hours and the mean terminal half-life 7.9 to 10.5 hours; with multiple dosing, steady state was reached by about day 5, the mean accumulation ratio for AUC0–24 was 1.15 to 1.19, the mean half-life on day 7 was 9.1 to 11.9 hours, and 2.3% to 2.6% of the dose was excreted unchanged in urine. Exposure did not differ significantly between women and men or between older and younger adults. The capsule used in this study gives about 50% of the exposure of the tablet used in the phase 2 study.
In vitro, lorundrostat inhibited CYP11B2 with 374-fold selectivity over CYP11B1. Single doses of 10 to 800 mg reduced the plasma aldosterone AUC0–24 by 36% to 77% compared with placebo without affecting cortisol, multiple doses completely blunted the ACTH-stimulated aldosterone response with no effect on the cortisol response, and plasma aldosterone rebounded by 73% to 163% compared with placebo from 24 hours after the last dose. The authors state that dose selection for hypertension “should avoid the higher dose level and focus on doses up to 120 mg daily”. No serious treatment-emergent adverse events occurred; treatment-emergent adverse events were reported in 41 of 87 participants receiving lorundrostat (47%) and 18 of 29 receiving placebo (62%), mild dizziness in 9 (10.3%) and 1 (3.4%), and one participant was withdrawn after a single 360 mg dose because of sinus tachycardia. Within 2 days of multiple dosing, serum potassium rose by group means of 0.28 to 0.38 mmol/L, and no participant reached the stopping criterion of 6.0 mmol/L. In a concentration-QTc analysis of the same study, a placebo-corrected QTcF effect above 10 ms was excluded at plasma concentrations up to about 7800 ng/mL, 4.8-fold the predicted Cmax at 100 mg once daily, and the regulatory requirement for a thorough QT study was waived.
Summary: hyperkalemia, hyponatremia, and eGFR across trials
No integrated safety analysis across trials was located; the figures below come from the individual trials, and hyperkalemia rates depend on whether a single value or a value confirmed by repeat testing is counted. In Launch-HTN, serum potassium above 6.0 mmol/L occurred in 4 participants (1.5%) in the escalation group, 6 (1.1%) in the 50 mg group, and 2 (0.7%) in the placebo group; after exclusion of spurious results, the annual report gives confirmed hyperkalemia of 1.1% and 0.6% in the two lorundrostat groups. Hyperkalemia requiring trial drug modification occurred in 7 (2.6%), 11 (2.0%), and 1 (0.4%) Launch-HTN participants, and 1 (0.37%) and 2 (0.37%) in the two lorundrostat groups discontinued for hyperkalemia. In Advance-HTN, potassium above 6.0 mmol/L occurred in 5% and 7% of the two lorundrostat groups and none of the placebo group in the publication abstract (5.3% and 7.4% in the annual report), and in 2.1% and 3.2% after confirmation. In Target-HTN, 6 participants (3.6%) had potassium above 6.0 mmol/L. In Explore-CKD, hyperkalemia was reported in 15.5% of participants during lorundrostat treatment and 3.5% during placebo, 3 participants (5.2%) had confirmed potassium above 6.0 mmol/L, and 5 (8.6%) had a dose modification for hyperkalemia. In Explore-OSA, no potassium value exceeded 5.5 mmol/L, and in the Transform-HTN extension 16 participants (2.5%) had confirmed potassium above 6.0 mmol/L and 10 (1.6%) discontinued for hyperkalemia.
In Launch-HTN, hyponatremia requiring trial drug modification occurred in 28 (10.4%), 37 (6.9%), and 9 (3.3%) participants in the escalation, 50 mg, and placebo groups, serum sodium below 125 mmol/L in 4 (1.5%), 4 (0.7%), and 1 (0.4%), and 1 (0.37%) and 2 (0.37%) lorundrostat-treated participants discontinued for hyponatremia. Hyponatremia was reported in 9% and 11% of the two Advance-HTN lorundrostat groups and 6% of the placebo group, in 5.2% of participants during lorundrostat treatment and 5.3% during placebo in Explore-CKD (with no serum sodium value below 125 mmol/L), and as requiring trial drug modification in 28 (4.4%) Transform-HTN participants. In Target-HTN, the 1 treatment-related serious adverse event was worsening hyponatremia that required stopping the drug.
In Launch-HTN, creatinine-based eGFR decreased by 9.3% from baseline to week 12 in both lorundrostat groups and increased by 0.4% with placebo, and cystatin C-based eGFR decreased by 5.2% and 4.1% and increased by 3.4% with placebo; the investigators describe the decline as expected and use the cystatin C equation to correct for creatinine elevation caused by competition between lorundrostat and creatinine for MATE1-dependent transport. Reduction in eGFR requiring trial drug modification occurred in 9 (3.3%), 16 (3.0%), and 2 (0.7%) Launch-HTN participants, and 3 (0.56%) in the 50 mg group discontinued for it. In Explore-CKD, the placebo-adjusted change was −1.97 mL/min/1.73 m2 (95% CI, −3.83 to −0.11; P = 0.0380) in cystatin C-estimated eGFR and −6.09 mL/min/1.73 m2 (95% CI, −8.12 to −4.05; P < 0.0001) in creatinine-estimated eGFR; 9 participants had a cystatin C eGFR decrease of 25% or more, none had a decrease of 50% or more, and 6 (10.3%) had a dose modification for reduced kidney function. In Transform-HTN, the company reports that eGFR decreased early in treatment and remained stable through week 48.